Spyre Therapeutics announced positive Phase 2 trial results for its SPY001 drug in inflammatory bowel disease, showing strong efficacy and safety. The company also accelerated enrollment and topline data for its rheumatoid arthritis trial, with multiple data readouts expected in 2026. Spyre raised $463 million in a public offering, boosting its cash reserves to $1.2 billion, supporting operations through mid-2029. These developments position Spyre to advance its pipeline targeting IBD and rheumatic diseases with innovative long-acting antibody therapies.
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
Charles Hoskinson, co-founder of Cardano, warned that Bitcoin might lose its top cryptocurrency status if its governance structure fails to effectively address quantum computing challenges. He emphasized that Bitcoin's rigidity in making major upgrad...
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
Singapore's Monetary Authority has slightly increased the rate of appreciation of the Singapore dollar's policy band for the second time, aiming to preempt inflation risks from rising oil prices. Despite core inflation remaining low at 1.6% in June, ...
POSCO International, South Korea's largest trading company, is piloting the tokenization of real commercial invoices on the Injective blockchain in partnership with LG CNS. This pilot creates a unified, transferable onchain record for trade receivabl...
